Interaction Checker

Interaksi Temsirolimus

Temsirolimus (Torisel) memiliki 215 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 2 mayor, 212 moderat, 1 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (2)

  • Itrakonazolantijamur azolMayor

    Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (label Itrakonazol, Interaksi obat)

  • KarbamazepinantikonvulsanMayor

    Temsirolimus The use of concomitant strong CYP3A4 inducers such as carbamazepine should be avoided with temsirolimus. (label Karbamazepin, Interaksi obat)

Interaksi moderat (212)

  • AbataseptimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • Abrositinibpenghambat JAKModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • AdalimumabimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • AkarbosaantidiabetesModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • AlemtuzumabimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • Alogliptinpenghambat DPP-4Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Alogliptin dan metforminpenghambat DPP-4Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • AmiodaronantiaritmiaModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Amlodipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Amlodipin dan atorvastatinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Amlodipin dan benazeprilpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Amlodipin dan olmesartanpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Amlodipin dan valsartanpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Aprepitantpenghambat CYP3A4Moderat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Armodafinilstimulan SSPModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • AtazanavirantiretroviralModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • AzatioprinimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • AzelastinantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • Azelastin dan flutikasonantihistaminModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • Barisitinibpenghambat JAKModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • BeklometasonkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • Beksagliflozinpenghambat SGLT2Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Benazeprilpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Benazepril dan hidroklorotiazidpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • BetametasonkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • Bosentanpenginduksi CYP3A4Moderat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Bromfeniramin, pseudoefedrin, dan dekstrometorfanantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • BudesonidkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • Budesonid dan formoterolkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • Dapagliflozinpenghambat SGLT2Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Dapagliflozin dan metforminpenghambat SGLT2Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • DarunavirantiretroviralModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Darunavir dan kobisistatantiretroviralModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Deferasirokssuplemen zat besiModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • DeflazakortkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • DeksametasonkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • DeksklorfeniraminantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • DesloratadinantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • DesonidkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • DifenhidraminantihistaminModerat

    At the discretion of the physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting… (label Temsirolimus, Peringatan dan perhatian)

  • Diltiazempenghambat kanal kalsiumModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • DimenhidrinatantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • Dimetil fumaratimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • DoksilaminantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • Doksilamin dan piridoksinantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • DronedaronantiaritmiaModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Dulaglutidagonis reseptor GLP-1Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • EfavirenzantiretroviralModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Eksenatidagonis reseptor GLP-1Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Empagliflozinpenghambat SGLT2Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Empagliflozin dan metforminpenghambat SGLT2Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Enalaprilpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Enalapril dan hidroklorotiazidpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Enalaprilatpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Eritromisinantibiotik makrolidaModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • EslikarbazepinantikonvulsanModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • EtanerseptimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • EtravirinantiretroviralModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • EverolimusimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • Famotidinpenghambat H2Moderat

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (label Temsirolimus, Peringatan dan perhatian)

  • FeksofenadinantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • Felodipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • FenitoinantikonvulsanModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • FenobarbitalbarbituratModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Fenobarbital, hiosiamin, atropin, dan skopolaminbarbituratModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Fentermin dan topiramatstimulan SSPModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • FingolimodimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • FludrokortisonkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • Flukonazolantijamur azolModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • FlunisolidkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • FluosinonidkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • FlutikasonkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • Flutikason dan salmeterolkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • FosamprenavirantiretroviralModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Fosaprepitantpenghambat CYP3A4Moderat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • FosfenitoinantikonvulsanModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Fosinoprilpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Fosinopril dan hidroklorotiazidpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • GlibenklamidsulfonilureaModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Glibenklamid dan metforminsulfonilureaModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • GlimepiridsulfonilureaModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • GlipizidsulfonilureaModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Glipizid dan metforminsulfonilureaModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • GriseofulvinantijamurModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • GuselkumabimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • HalobetasolkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • Hidrokodon dan klorfeniraminopioidModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • HidrokortisonkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • HidroksizinantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • Ibuprofen dan famotidinOAINSModerat

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (label Temsirolimus, Peringatan dan perhatian)

  • Imatinibpenghambat CYP3A4Moderat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • InfliksimabimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • Insulin aspartinsulinModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Insulin degludekinsulinModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Insulin detemirinsulinModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Insulin glargininsulinModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Insulin lisproinsulinModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Insulin reguler (manusia)insulinModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • IsoniazidantibiotikModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Isradipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Moderat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Kanagliflozinpenghambat SGLT2Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Kaptoprilpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • KarbinoksaminantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • Ketokonazolantijamur azolModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • KladribinantimetabolitModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • Klaritromisinantibiotik makrolidaModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • KlemastinantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • KlobazambenzodiazepinModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • KlobetasolkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • KlorfeniraminantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • Kuinaprilpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Kuinapril dan hidroklorotiazidpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • LeflunomidimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • LenakapavirantiretroviralModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • LevosetirizinantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • Linagliptinpenghambat DPP-4Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Linagliptin dan metforminpenghambat DPP-4Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Liraglutidagonis reseptor GLP-1Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Lisinoprilpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Lisinopril dan hidroklorotiazidpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • LoratadinantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • Lorlatinibpenginduksi CYP3A4Moderat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • MeklizinantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • MerkaptopurinantimetabolitModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • MetforminbiguanidModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • MetilprednisolonkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • MetotreksatimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • Mifepristonpenghambat CYP3A4Moderat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • MiglitolantidiabetesModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • MikofenolatimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • Mirabegronagonis beta-adrenergikModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Mitapivatpenginduksi CYP3A4Moderat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Mitotanpenginduksi CYP3A4Moderat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Modafinilstimulan SSPModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Moeksiprilpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • MometasonkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • Nafsilinantibiotik penisilinModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • NatalizumabimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • NateglinidmeglitinidModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • NefazodonantidepresanModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • NevirapinantiretroviralModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Nifedipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Nikardipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Nimodipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Nisoldipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Nizatidinpenghambat H2Moderat

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (label Temsirolimus, Peringatan dan perhatian)

  • OkrelizumabimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • OkskarbazepinantikonvulsanModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • OlopatadinantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • Olopatadin dan mometasonantihistaminModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • Palbosiklibpenghambat CYP3A4Moderat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • PerampanelantikonvulsanModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Perindoprilpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Pimekrolimuspenghambat kalsineurinModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • PioglitazontiazolidindionModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Pioglitazon dan glimepiridtiazolidindionModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Pioglitazon dan metformintiazolidindionModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • PonesimodimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • Posakonazolantijamur azolModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • PrednisolonkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • PrednisonkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • PrimidonantikonvulsanModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • PrometazinantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • Prometazin dan dekstrometorfanantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • Prometazin dan kodeinopioidModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • Ramiprilpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • Ranitidinpenghambat H2Moderat

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (label Temsirolimus, Peringatan dan perhatian)

  • Ranolazinobat yang memperpanjang interval QTModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • RepaglinidmeglitinidModerat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • RifabutinantibiotikModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • RifampisinantibiotikModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • RifapentinantibiotikModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Ritlesitinibpenghambat JAKModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • RitonavirantiretroviralModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • RituksimabimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • Saksagliptinpenghambat DPP-4Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Saksagliptin dan metforminpenghambat DPP-4Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • SekukinumabimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • Semaglutidagonis reseptor GLP-1Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • SenobamatantikonvulsanModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • SetirizinantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • SiklesonidkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • SiklofosfamidimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • SiklosporinimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • Simetidinpenghambat H2Moderat

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (label Temsirolimus, Peringatan dan perhatian)

  • SiproheptadinantihistaminModerat

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • SirolimusimunosupresanModerat

    TORISEL should be used with caution in persons with known hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any other component (including the excipients) of TORISEL. (label Temsirolimus, Peringatan dan perhatian)

  • Sitagliptinpenghambat DPP-4Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • Sitagliptin dan metforminpenghambat DPP-4Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • SunitinibModerat

    Concomitant use of TORISEL with sunitinib The combination of TORISEL and sunitinib resulted in dose-limiting toxicity. (label Temsirolimus, Peringatan dan perhatian)

  • Suvoreksantsedatif-hipnotikModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Suzetriginpenginduksi CYP3A4Moderat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • TakrolimusimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • Telmisartan dan amlodipinpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • TeriflunomidimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • TikagrelorantiplateletModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Tirzepatidagonis reseptor GLP-1Moderat

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

  • TofasitinibimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • TopiramatantikonvulsanModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • TosilizumabimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • Trandolaprilpenghambat ACEModerat

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

  • TriamsinolonkortikosteroidModerat

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • UpadasitinibimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • UstekinumabimunosupresanModerat

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (label Temsirolimus, Peringatan dan perhatian)

  • Verapamilpenghambat kanal kalsiumModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

  • Vorikonazolantijamur azolModerat

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (label Temsirolimus, Peringatan dan perhatian)

Penyebutan minor (1)

  • Desipraminantidepresan trisiklikMinor

    Drug Interactions Effect of Temsirolimus on CYP2D6 or CYP3A The concentration of desipramine, a CYP2D6 substrate, was unaffected when 25 mg of temsirolimus was co-administered. (label Temsirolimus, Interaksi obat)

Periksa Temsirolimus terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.